Nova Mentis Life Science Corp. (NOVA.CN)
CAD 0.01
(-50.0%)
CAD 0.01
(-50.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.2 Million CAD | -3.02% |
| 2022 | -1.84 Million CAD | 62.12% |
| 2021 | -2.79 Million CAD | -115.66% |
| 2020 | -1.57 Million CAD | 1873.23% |
| 2019 | -1.21 Million CAD | 69.62% |
| 2018 | -3.45 Million CAD | -111.01% |
| 2017 | -1.86 Million CAD | 6.3% |
| 2016 | -2.07 Million CAD | -155.5% |
| 2015 | -684.8 Thousand CAD | -166.76% |
| 2014 | -2.06 Million CAD | 1062.1% |
| 2013 | -261.42 Thousand CAD | 82.81% |
| 2012 | -6.59 Million CAD | 32.96% |
| 2011 | -3.3 Million CAD | -40.98% |
| 2010 | -2.65 Million CAD | 62.32% |
| 2009 | -1.85 Million CAD | -147.13% |
| 2008 | -745.7 Thousand CAD | -21.17% |
| 2007 | -601.45 Thousand CAD | -503.79% |
| 2006 | -100.7 Thousand CAD | -63.44% |
| 2005 | -62.24 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -90.17 Thousand CAD | 37.41% |
| 2024 Q1 | -144.98 Thousand CAD | 31.13% |
| 2023 Q2 | -302.06 Thousand CAD | 42.71% |
| 2023 Q1 | -527.27 Thousand CAD | -255.57% |
| 2023 Q4 | -209.94 Thousand CAD | -10.52% |
| 2023 Q3 | -189.95 Thousand CAD | 37.11% |
| 2023 FY | - CAD | -5.32% |
| 2022 Q4 | 338.93 Thousand CAD | 174.98% |
| 2022 FY | - CAD | 62.12% |
| 2022 Q1 | -661.17 Thousand CAD | -13.87% |
| 2022 Q2 | -392.83 Thousand CAD | 40.58% |
| 2022 Q3 | -452.02 Thousand CAD | -15.07% |
| 2021 Q4 | -580.63 Thousand CAD | 60.24% |
| 2021 FY | - CAD | -115.66% |
| 2021 Q3 | -1.46 Million CAD | -245.3% |
| 2021 Q2 | -422.93 Thousand CAD | 31.45% |
| 2021 Q1 | -616.99 Thousand CAD | -104.37% |
| 2020 Q4 | 14.12 Million CAD | 3106.99% |
| 2020 Q1 | -118.85 Thousand CAD | -921.74% |
| 2020 FY | - CAD | 1873.23% |
| 2020 Q2 | 6.13 Million CAD | 5265.76% |
| 2020 Q3 | -469.73 Thousand CAD | -107.65% |
| 2019 Q3 | -466.87 Thousand CAD | -67.29% |
| 2019 Q2 | -279.07 Thousand CAD | 20.73% |
| 2019 Q1 | -352.04 Thousand CAD | 33.75% |
| 2019 Q4 | -11.63 Thousand CAD | 97.51% |
| 2019 FY | - CAD | 69.62% |
| 2018 Q2 | -286.41 Thousand CAD | 86.45% |
| 2018 Q3 | -702.42 Thousand CAD | -145.24% |
| 2018 FY | - CAD | -111.01% |
| 2018 Q1 | -2.11 Million CAD | -166.19% |
| 2018 Q4 | -531.42 Thousand CAD | 24.34% |
| 2017 Q3 | -336 Thousand CAD | -0.39% |
| 2017 FY | - CAD | 6.3% |
| 2017 Q2 | -334.7 Thousand CAD | -25.78% |
| 2017 Q1 | -266.1 Thousand CAD | 83.21% |
| 2017 Q4 | -793.84 Thousand CAD | -136.26% |
| 2016 Q3 | -193.9 Thousand CAD | -1242.43% |
| 2016 Q1 | -85.04 Thousand CAD | 64.97% |
| 2016 FY | - CAD | -155.5% |
| 2016 Q2 | 16.97 Thousand CAD | 119.96% |
| 2016 Q4 | -1.58 Million CAD | -717.56% |
| 2015 FY | - CAD | -166.76% |
| 2015 Q1 | -170.35 Thousand CAD | -111.83% |
| 2015 Q2 | -120.04 Thousand CAD | 29.53% |
| 2015 Q3 | -189.8 Thousand CAD | -58.11% |
| 2015 Q4 | -242.79 Thousand CAD | -27.91% |
| 2014 Q1 | -72.33 Thousand CAD | -168.99% |
| 2014 Q4 | 1.44 Million CAD | 1101.76% |
| 2014 FY | - CAD | 1062.1% |
| 2014 Q3 | -143.81 Thousand CAD | -1.62% |
| 2014 Q2 | -141.51 Thousand CAD | -95.65% |
| 2013 Q1 | -57.01 Thousand CAD | 61.33% |
| 2013 FY | - CAD | 82.81% |
| 2013 Q2 | -67.94 Thousand CAD | -19.18% |
| 2013 Q4 | 104.83 Thousand CAD | 215.36% |
| 2013 Q3 | -90.87 Thousand CAD | -33.75% |
| 2012 Q1 | -158.23 Thousand CAD | 50.63% |
| 2012 FY | - CAD | 32.96% |
| 2012 Q3 | -211.27 Thousand CAD | -64.05% |
| 2012 Q4 | -147.42 Thousand CAD | 30.22% |
| 2012 Q2 | -128.78 Thousand CAD | 18.61% |
| 2011 Q2 | -282.71 Thousand CAD | -61.59% |
| 2011 Q1 | -174.95 Thousand CAD | 87.47% |
| 2011 Q3 | -198.75 Thousand CAD | 29.7% |
| 2011 FY | - CAD | -40.98% |
| 2011 Q4 | -320.51 Thousand CAD | -61.26% |
| 2010 Q3 | 15.81 Thousand CAD | 109.56% |
| 2010 Q1 | 852.96 Thousand CAD | 314.46% |
| 2010 Q4 | -1.39 Million CAD | -8928.0% |
| 2010 Q2 | -165.43 Thousand CAD | -119.4% |
| 2010 FY | - CAD | 62.32% |
| 2009 Q4 | -397.72 Thousand CAD | 13.43% |
| 2009 FY | - CAD | -147.13% |
| 2009 Q3 | -459.44 Thousand CAD | -22.19% |
| 2009 Q2 | -375.99 Thousand CAD | 37.95% |
| 2009 Q1 | -605.93 Thousand CAD | -231.02% |
| 2008 Q2 | -188.09 Thousand CAD | -265.2% |
| 2008 Q3 | -322.67 Thousand CAD | -71.55% |
| 2008 FY | - CAD | -21.17% |
| 2008 Q1 | -51.5 Thousand CAD | 83.48% |
| 2008 Q4 | -183.05 Thousand CAD | 43.27% |
| 2007 Q4 | -311.79 Thousand CAD | -205.82% |
| 2007 Q1 | -96.54 Thousand CAD | -78.92% |
| 2007 Q3 | -101.95 Thousand CAD | -7.64% |
| 2007 Q2 | -94.71 Thousand CAD | 1.89% |
| 2007 FY | - CAD | -503.79% |
| 2006 Q3 | -17.05 Thousand CAD | -13.23% |
| 2006 FY | - CAD | -63.44% |
| 2006 Q1 | 148.00 CAD | 0.0% |
| 2006 Q4 | -53.95 Thousand CAD | -216.39% |
| 2006 Q2 | -15.06 Thousand CAD | -10276.35% |
| 2005 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -4.98 Million CAD | 75.865% |
| Asep Medical Holdings Inc | -8.13 Million CAD | 85.222% |
| BetterLife Pharma Inc. | -3.19 Million CAD | 62.328% |
| BioVaxys Technology Corp. | -7.68 Million CAD | 84.36% |
| ChitogenX Inc. | -2.69 Million CAD | 55.371% |
| Rapid Dose Therapeutics Corp. | -3.02 Million CAD | 60.251% |
| Defence Therapeutics Inc. | -12.67 Million CAD | 90.515% |
| Entheon Biomedical Corp. | 13.99 Thousand CAD | 8692.146% |
| Gemina Laboratories Ltd. | -5.17 Million CAD | 76.771% |
| Glow Lifetech Corp. | -1.26 Million CAD | 4.809% |
| Lexston Life Sciences Corp. | -648.32 Thousand CAD | -85.447% |
| Pharmala Biotech Holdings Inc. | -710.18 Thousand CAD | -69.294% |
| Doseology Sciences Inc. | -319.47 Thousand CAD | -276.332% |
| MYND Life Sciences Inc. | -1.82 Million CAD | 34.128% |
| PharmaTher Holdings Ltd. | -3.04 Million CAD | 60.494% |
| PreveCeutical Medical Inc. | -955.08 Thousand CAD | -25.884% |
| Telescope Innovations Corp. | -5.49 Million CAD | 78.102% |